Research programme: macrophage checkpoint inhibitors - Pheast Therapeutics
Latest Information Update: 28 May 2026
At a glance
- Originator Pheast Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action CD24 antigen inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 May 2026 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 May 2026 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
- 28 May 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA